Clinical trial
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in…
NCT00433017 · Novartis, Industry · Terminated
Key facts
| NCT number | NCT00433017 |
|---|---|
| Title | Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) |
| Official title | 24-month Randomized, Double-masked, Controlled, Multicenter, Phase II Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to AMD. |
| Lead sponsor | Novartis, Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Macular Degeneration, Choroidal Neovascularization |
| Intervention type | Drug |
| Interventions | Verteporfin Photodynamic Therapy, Ranibizumab, Placebo |
| Enrollment | 255 |
| Start date | May 1, 2007 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Feb 9, 2007 |
| Last update posted | Apr 21, 2011 |
| Countries | Austria, Belgium, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: